Merck to acquire Verona Pharma for $10 billion
Published by Global Banking & Finance Review®
Posted on July 9, 2025
1 min readLast updated: January 23, 2026
Published by Global Banking & Finance Review®
Posted on July 9, 2025
1 min readLast updated: January 23, 2026
Merck will acquire UK-based Verona Pharma for $10 billion, enhancing its respiratory treatment portfolio as it prepares for a major patent expiry.
(Reuters) -Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)
Merck will acquire Verona Pharma for approximately $10 billion.
The acquisition is aimed at strengthening Merck's presence in respiratory treatments.
Verona Pharma is based in the UK.
The acquisition was reported by Reuters.
Merck is preparing for the patent expiration in the respiratory treatment market.
Explore more articles in the Finance category




